And for more aggressive investors, I'll talk about a riskier clinical-stage biotech company offering an investigational coronavirus vaccine and potential for regulatory approval of another product on the horizon.But at $2,340 per patient for a five-day treatment course, and considering a Journal of Virus Eradication report estimating it costs less than a dollar to produce a one-day dose of remdesivir, it's likely Gilead will make a profit.